Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
equine allogeneic cartibeads
- Development stage
- Preclinical
- Lead developer
- Vanarix
- Modality
- Cell Therapies
- Administration
- Intraarticular
01
Overview
Equine allogeneic cartibeads is an allogeneic cell therapy developed by Vanarix for the treatment of osteochondritis dissecans in horses. The therapy consists of bioengineered, bead-shaped cartilage mini-implants (microtissues) produced from donor equine chondrocytes. Through a patented process, the chondrocytes undergo dedifferentiation and redifferentiation to generate high-quality hyaline-like cartilage matrix. When implanted into focal cartilage lesions, these cartibeads self-integrate into the surrounding tissue to regenerate damaged articular cartilage without requiring tissue compatibility.
- Brand names
- Cartibeads
- Other names
- Equine Cartibeads
Beyond the preview
Go deeper on equine allogeneic cartibeads.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on equine allogeneic cartibeads.